drugset / Trial / NCT00176878
Stem Cell Transplant for Bone Marrow Failure Syndromes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.
Timeline
- Start
- 2000-06
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 15 mg/kg | Other |
| Background | Busulfan | Small molecule | 8 mg/kg | Oral |
| Background | Fludarabine | Small molecule | 175 mg/m2 | Other |